Atlas Trials

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Clinical trial NCT01491737 · COMPLETED

Trial details

NCT number
NCT01491737
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2012-02-17
Primary completion
2016-03-17
Enrollment
258

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.